Integrating metabolic expenditure information from wearable fitness sensors into an AI-augmented automated insulin delivery system: a randomised clinical trial.

Autor:	Jacobs PG; Artificial Intelligence for Medical Systems Lab, Department of Biomedical Engineering, Center for Health and Healing, Oregon Health and Science University, Portland, OR, USA. Electronic address: jacobsp@ohsu.edu., Resalat N; Artificial Intelligence for Medical Systems Lab, Department of Biomedical Engineering, Center for Health and Healing, Oregon Health and Science University, Portland, OR, USA., Hilts W; Artificial Intelligence for Medical Systems Lab, Department of Biomedical Engineering, Center for Health and Healing, Oregon Health and Science University, Portland, OR, USA., Young GM; Artificial Intelligence for Medical Systems Lab, Department of Biomedical Engineering, Center for Health and Healing, Oregon Health and Science University, Portland, OR, USA., Leitschuh J; Artificial Intelligence for Medical Systems Lab, Department of Biomedical Engineering, Center for Health and Healing, Oregon Health and Science University, Portland, OR, USA., Pinsonault J; Artificial Intelligence for Medical Systems Lab, Department of Biomedical Engineering, Center for Health and Healing, Oregon Health and Science University, Portland, OR, USA., El Youssef J; Harold Schnitzer Diabetes Health Center, Oregon Health and Science University, Portland, OR, USA., Branigan D; Harold Schnitzer Diabetes Health Center, Oregon Health and Science University, Portland, OR, USA., Gabo V; Harold Schnitzer Diabetes Health Center, Oregon Health and Science University, Portland, OR, USA., Eom J; Harold Schnitzer Diabetes Health Center, Oregon Health and Science University, Portland, OR, USA., Ramsey K; Oregon Clinical and Translational Research Institute Biostatistics and Design Program, Oregon Health and Science University, Portland, OR, USA., Dodier R; Artificial Intelligence for Medical Systems Lab, Department of Biomedical Engineering, Center for Health and Healing, Oregon Health and Science University, Portland, OR, USA., Mosquera-Lopez C; Artificial Intelligence for Medical Systems Lab, Department of Biomedical Engineering, Center for Health and Healing, Oregon Health and Science University, Portland, OR, USA., Wilson LM; Harold Schnitzer Diabetes Health Center, Oregon Health and Science University, Portland, OR, USA., Castle JR; Harold Schnitzer Diabetes Health Center, Oregon Health and Science University, Portland, OR, USA.
Jazyk:	angličtina
Zdroj:	The Lancet. Digital health [Lancet Digit Health] 2023 Sep; Vol. 5 (9), pp. e607-e617. Date of Electronic Publication: 2023 Aug 03.
DOI:	10.1016/S2589-7500(23)00112-7
Abstrakt:	Background: Exercise can rapidly drop glucose in people with type 1 diabetes. Ubiquitous wearable fitness sensors are not integrated into automated insulin delivery (AID) systems. We hypothesised that an AID can automate insulin adjustments using real-time wearable fitness data to reduce hypoglycaemia during exercise and free-living conditions compared with an AID not automating use of fitness data. Methods: Our study population comprised of individuals (aged 21-50 years) with type 1 diabetes from from the Harold Schnitzer Diabetes Health Center clinic at Oregon Health and Science University, OR, USA, who were enrolled into a 76 h single-centre, two-arm randomised (4-block randomisation), non-blinded crossover study to use (1) an AID that detects exercise, prompts the user, and shuts off insulin during exercise using an exercise-aware adaptive proportional derivative (exAPD) algorithm or (2) an AID that automates insulin adjustments using fitness data in real-time through an exercise-aware model predictive control (exMPC) algorithm. Both algorithms ran on iPancreas comprising commercial glucose sensors, insulin pumps, and smartwatches. Participants executed 1 week run-in on usual therapy followed by exAPD or exMPC for one 12 h primary in-clinic session involving meals, exercise, and activities of daily living, and 2 free-living out-patient days. Primary outcome was time below range (<3·9 mmol/L) during the primary in-clinic session. Secondary outcome measures included mean glucose and time in range (3·9-10 mmol/L). This trial is registered with ClinicalTrials.gov, NCT04771403. Findings: Between April 13, 2021, and Oct 3, 2022, 27 participants (18 females) were enrolled into the study. There was no significant difference between exMPC (n=24) versus exAPD (n=22) in time below range (mean [SD] 1·3% [2·9] vs 2·5% [7·0]) or time in range (63·2% [23·9] vs 59·4% [23·1]) during the primary in-clinic session. In the 2 h period after start of in-clinic exercise, exMPC had significantly lower mean glucose (7·3 [1·6] vs 8·0 [1·7] mmol/L, p=0·023) and comparable time below range (1·4% [4·2] vs 4·9% [14·4]). Across the 76 h study, both algorithms achieved clinical time in range targets (71·2% [16] and 75·5% [11]) and time below range (1·0% [1·2] and 1·3% [2·2]), significantly lower than run-in period (2·4% [2·4], p=0·0004 vs exMPC; p=0·012 vs exAPD). No adverse events occurred. Interpretation: AIDs can integrate exercise data from smartwatches to inform insulin dosing and limit hypoglycaemia while improving glucose outcomes. Future AID systems that integrate exercise metrics from wearable fitness sensors may help people living with type 1 diabetes exercise safely by limiting hypoglycaemia. Funding: JDRF Foundation and the Leona M and Harry B Helmsley Charitable Trust, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Competing Interests: Declaration of interests PGJ and JRC have a financial interest in Pacific Diabetes Technologies, a company that might have a commercial interest in the results of this research and technology. JRC also reports advisory board participation for Zealand Pharma, Novo Nordisk, Insulet, and AstraZeneca. PGJ reports advisory board participation for Eli Lilly. PGJ and JRC have received research funding at their institution from Dexcom. All other authors declare no competing interests. (Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu